Figure 2 | Cell Death Discovery

Figure 2

From: Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer

Figure 2

Identification of GW8510 as a potential RRM2 inhibitor. (a) The chemical structures of GW8510. (b) HCT116 cells were treated with various doses of GW8510 for 72 h. The cell viability was analyzed by an MTT assay. (c) HCT116 cells were treated with various doses of GW8510 for 24 h. The protein expressions were analyzed by western blots. (d) HCT116 cells were treated with various doses of GW8510 for 24 h in the absence or presence of 5 μM MG132. The protein expressions were analyzed by western blots. (e) HCT116 cells were transiently transfected with a RRM2-overexpressing (pcDNA3-RRM2) or a control (pcDNA3) plasmid for 48 h, and then treated with indicated doses of GW8510 for 24 h. The protein expressions were analyzed by western blots. (f) HCT116 cells were transiently transfected with a RRM2-overexpressing (pcDNA3-RRM2) or a control (pcDNA3) plasmid for 24 h, and then treated with indicated doses of GW8510 for 72 h. The cell viability was analyzed by an MTT assay.

Back to article page